Literature DB >> 9396013

Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.

P Monteleone1, M Natale, A La Rocca, M Maj.   

Abstract

To evaluate the biosynthetic activity of the pineal gland in schizophrenia, the circadian rhythm of plasma melatonin was investigated in 9 drug-free chronic schizophrenics and in matched healthy subjects. In 7 of the patients, the 24-hour secretory pattern of the pineal hormone was reassessed after 10 weeks of treatment with antipsychotic drugs. In drug-free schizophrenics, the nocturnal increase in plasma melatonin levels was significantly blunted as compared to healthy subjects (p < 0.0001). Chronic treatment with antipsychotic drugs significantly improved psychotic symptomatology, but did not change the secretory pattern of melatonin. These data show that the biosynthetic activity of the pineal gland is impaired in chronic schizophrenia and that successful treatment with antipsychotic drugs does not go parallel with changes in the production of melatonin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396013     DOI: 10.1159/000119377

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  15 in total

1.  Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia.

Authors:  Christina P C Borba; Xiaoduo Fan; Paul M Copeland; Alexander Paiva; Oliver Freudenreich; David C Henderson
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

2.  Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia.

Authors:  Cigdem Sahbaz; Omer Faruk Özer; Ayse Kurtulmus; Ismet Kırpınar; Fikrettin Sahin; Sinan Guloksuz
Journal:  Metab Brain Dis       Date:  2019-02-13       Impact factor: 3.584

Review 3.  Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.

Authors:  George Anderson; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-04-25       Impact factor: 3.584

4.  Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients.

Authors:  Hae Jeong Park; Jin Kyung Park; Su Kang Kim; Ah-Rang Cho; Jong Woo Kim; Sung-Vin Yim; Joo-Ho Chung
Journal:  J Mol Neurosci       Date:  2011-04-28       Impact factor: 3.444

5.  Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects.

Authors:  Stefan Cohrs; Kathrin Pohlmann; Zhenghua Guan; Wolfgang Jordan; Andreas Meier; Gerald Huether; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

6.  Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure.

Authors:  Abla Benleulmi-Chaachoua; Alan Hegron; Marine Le Boulch; Angeliki Karamitri; Marta Wierzbicka; Victoria Wong; Igor Stagljar; Philippe Delagrange; Raise Ahmad; Ralf Jockers
Journal:  Cell Mol Life Sci       Date:  2018-07-24       Impact factor: 9.261

7.  Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial.

Authors:  Yukihiko Shirayama; Michio Takahashi; Masatoshi Suzuki; Yoshiaki Tsuruoka; Koichi Sato
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

Review 8.  Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.

Authors:  Lindsay M Melhuish Beaupre; Gregory M Brown; Vanessa F Gonçalves; James L Kennedy
Journal:  Transl Psychiatry       Date:  2021-06-02       Impact factor: 6.222

Review 9.  Role of melatonin in schizophrenia.

Authors:  Armando L Morera-Fumero; Pedro Abreu-Gonzalez
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

Review 10.  Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review.

Authors:  Megan Anne Arroll; Lorraine Wilder; James Neil
Journal:  Nutr J       Date:  2014-09-16       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.